<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/f5f6e2cc-06d4-4684-8d26-bf12e13cbbd2/HTML"><dcterms:extent>23 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/be7e4d59-e002-4017-ada0-ed33da5e30cc/PDF"><dcterms:extent>67 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/393766a3-afda-40a2-9cd8-6b4fd5b7d0d0/TEXT"><dcterms:extent>21 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-MWPKWMXA"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2010</dcterms:issued><dc:creator>Berginc, Katja</dc:creator><dc:creator>Kristl, Albin</dc:creator><dc:format xml:lang="sl">številka:3</dc:format><dc:format xml:lang="sl">letnik:61</dc:format><dc:format xml:lang="sl">str. 171-175</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:2827889</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-MWPKWMXA</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">citokromi</dc:subject><dc:subject xml:lang="sl">česen</dc:subject><dc:subject xml:lang="sl">farmacevtski preparati</dc:subject><dc:subject xml:lang="sl">interakcije</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Farmakološki učinki česnovih pripravkov in njihove interakcije z zdravilnimi učinkovinami| The pharmacological effects of garlic supplements and their interactions with prescribed therapy|</dc:title><dc:description xml:lang="sl">The consumption of commercially available garlic supplements especially by chronic patients is continuously rising due to disease preventing effects, recognized in numerous preclinical and clinical studies. However, combining inconventional therapy utilized drugs with garlic phytochemicals can lead to serious pharmacokinetic and pharmacodynamic interactions. Namely, in some cases significant plasma profile changes of applied drugs and their metabolites, caused by intestinal and hepatic CYP inhibition and/or altered efflux membrane transporter activity, have been recognized in the presence of garlic phytochemicals leading to therapeutic failure or toxic side effects. There are also reports on pharmacodynamic interactions between drugs with narrow therapeutic window (i.e. warfarin) and garlic. Therefore combining garlic supplements and certain drugs should be closely monitored or in some cases even discontinued</dc:description><dc:description xml:lang="sl">Zaradi farmakoloških učinkov česnovih pripravkov, dokazanih v predkliničnih in kliničnih študijah, po tovrstnih pripravkih posegajo številni kronični bolniki brez vednosti o potencialno nevarnih farmakokinetskih in farmakodinamskih interakcijah, ki se lahko razvijejo ob sočasno predpisani terapiji. Inhibicija encimov iz družine citokromov in/ali spremenjena aktivnost sekretornih prenašalcev v jetrih in črevesju ob prisotnosti nekaterih oeesnovih sestavin lahko pomembno spremeni profil plazemskih koncentracij apliciranih učinkovin in njihovih metabolitov, kar lahko vodi v terapevtsko neučinkovitost ali v toksične učinke. Zasledimo lahko tudi poročila o farmakodinamskih interakcijah med česnovimi pripravki in nekaterimi učinkovinami z ozkim terapevtskim oknom (npr. varfarinom). Zaradi naštetega se sočasna uporaba česnovih pripravkov z nekaterimi učinkovinami odsvetuje oz. je priporočeno terapevtsko spremljanje plazemskih koncentracij učinkovin</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-MWPKWMXA"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-MWPKWMXA" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/be7e4d59-e002-4017-ada0-ed33da5e30cc/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-MWPKWMXA/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-MWPKWMXA" /></ore:Aggregation></rdf:RDF>